Amendments to the Claims

1. (Previously presented) A pharmaceutical agent having serotonin 5-HT_7 receptor antagonist activity and muscarinic M_4 receptor agonist activity, for use in treating psychotic conditions, wherein the agent does not include compounds having a chemical structure falling within the following definition, namely:

bisarylazepines substituted at the azepine ring portion by a 4-methyl piperazinyl, wherein the aryl moieties are fused to the azepine ring and wherein aryl is phenyl, substituted phenyl, thienyl or substituted thienyl; including optional replacement of an azepine ring carbon atom with a nitrogen atom, or substitution of said ring carbon atom.

2. (Original) The pharmaceutical agent according to claim 1 wherein the psychotic condition is schizophrenia and/or bipolar disorder.

3. (Previously presented) The pharmaceutical agent according to claim 1 which comprises a mixture of at least two compounds, wherein at least one of said compounds possesses serotonin 5-HT_7 receptor antagonist activity and wherein at least one of said compounds possesses muscarinic M_4 receptor agonist activity.

4. (Previously presented) The pharmaceutical agent according to claim 1 which comprises a compound which possesses both serotonin 5-HT_7 receptor antagonist activity and muscarinic M_4 receptor agonist activity.

5. (Previously presented) The pharmaceutical agent according to claim 1 which additionally has a low or substantially no dopaminergic D_2 receptor affinity.

6. (Original) The pharmaceutical agent according to claim 5 wherein said dopaminergic D_2 receptor affinity is a minimum of at least 5 fold less than the affinity at the muscarinic M_4 and/or serotonin 5-HT_7 receptors.

7. (Original) The pharmaceutical agent according to claim 6 wherein said dopaminergic D_2 receptor affinity is at least 50 fold less than the affinity at the muscarinic M_4 and/or serotonin 5-HT_7 receptors.

8. (Previously presented) A pharmaceutical agent according to claim 1 for use in therapy.

9. (Previously presented) A pharmaceutical formulation comprising a pharmaceutical agent according to claim 1 together with a pharmaceutically acceptable carrier therefor.

10. (Previously presented) A method for the preparation of a medicament for the treatment or prophylaxis of schizophrenia and/or bipolar disorder, which comprises mixing the pharmaceutical agent according to claim 1 with a pharmaceutically acceptable carrier.

11. (Previously presented) A method of treating psychotic conditions in a patient in need thereof, comprising administering to the patient an effective amount of a pharmaceutical agent according to claim 1.

12. (Previously presented) A method of identifying an agent for use in treating psychotic conditions comprising the steps of:

a) providing an agent to be tested;

b) subjecting said agent to one or more test procedures to identify 5-HT_7 receptor antagonist activity and muscarinic M_4 receptor agonist activity of said agent; wherein the desired agent is considered to have been identified when said agent provides a 5-HT_7 receptor antagonist activity and a muscarinic M_4 receptor agonist activity.

13. (Original) The method according to claim 12 further comprising the step of subjecting the agent to a test procedure to identify low dopaminergic D_2 receptor affinity.

14. (Currently amended) A compound represented by formula (I):



(I)

where ~~R^1 and R^2 independently are a hydrogen atom, a substituted or unsubstituted straight chain or branched chain C_{1-6} alkyl group or C_{1-6} alkoxy group, a substituted or unsubstituted C_{3-8} cycloalkyl group or a C_{3-8} cycloalkoxy group, or an aralkyl group, or~~ R^1 and R^2 form, together with the nitrogen atom to which they are bonded, a cyclic amine which is substituted by a halogen atom, a C_{1-6} alkyl group or a C_{1-6} alkoxy group and/or wherein said cyclic amine is fused with a benzene ring; W and W' form, together with the benzene ring to which they are bonded, a fused five-membered, six-membered or seven-membered saturated carbocylic ring being independently unsubstituted, substituted or fully substituted at each carbon atom of the ring by a group – X-R^{13} where X is O, S, SO or SO_2 and R^{13} is a hydrogen atom, a C_{1-6} alkyl group, an acyl group, or an aroyl group or two of said –X-R^{13} groups, together with the carbon atom in the ring to which they are both bonded, form a C=S group or the following group:



where both of X' are O or S and Y is a C_{1-3} alkylene group.

15. (Canceled)

16. (Canceled)

17. (Currently amended) The compound according to claim ~~16~~ 14 wherein said benzene ring fused with said cyclic amine is substituted by one or two halogen atoms, C_{1-6} alkyl groups or C_{1-6} alkoxy groups.

18. (Currently amended) The compound according to claim 14 represented by the following formulae (II), (III) -or (IV):



(II)



(III)



(IV)

wherein ~~R^1 and R^2 independently are a hydrogen atom, a substituted or unsubstituted straight chain or branched chain C_{1-6} alkyl group or C_{1-6} alkoxy group, a substituted or unsubstituted C_{1-6} cycloalkyl group or a C_{1-6} cycloalkoxy group, or an aralkyl group, or~~ R^1 and R^2 form, together with the nitrogen atom to which they are bonded, a cyclic amine which is substituted by a halogen atom, a C_{1-6} alkyl group or a C_{1-6} alkoxy group and/or wherein said cyclic amine is fused with a benzene ring; R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, and R^{12} are independently a hydrogen atom or the group $-X-R^{13}$ wherein X is O, S, SO or SO_2 and R^{13} is a hydrogen atom, a C_{1-6} alkyl group, an acyl group, or an aroyl group or two of said $-X-R^{13}$ groups, together with the carbon atom in the ring to which they are both bonded, form a C=S group or the following group:



where both of X' are O or S and Y is a C_{1-3} alkylene group.

19. (Previously presented) The compound according to claim 18 wherein R^3 and R^4, R^5 and R^6, R^7 and R^8, R^9 and R^{10}, and/or R^{11} and R^{12} together with the carbon atom in the ring to which they are both bonded, form a C=S group or the following group:



wherein both of X' are O or S and Y is a C_{1-3} alkylene group.

20. (Previously presented) The compound according to claim 18 wherein R^1 and R^2 form together with the nitrogen atom to which they are bonded, a four-membered, five-membered or six-membered cyclic amine.

21. (Original) A compound according to claim 20 wherein said six-membered cyclic amine is fused with a benzene ring.

22. (Canceled)

23. (Previously presented) The compound according to claim 14 which possesses serotonin 5-HT_7 receptor antagonist activity and/or muscarinic M_4 receptor agonist activity.

24. (Currently amended) The compound according to claim 23 which additionally has a low or ~~substantially~~ no dopaminergic D_2 receptor affinity.

25. (Previously presented) The compound according to claim 14 for use in therapy.

26. (Previously presented) A pharmaceutical formulation comprising a compound according to claim 14 admixed with a pharmaceutically acceptable carrier.

27. (Previously presented) A method for the preparation of a medicament for the treatment or prophylaxis of schizophrenia and/or bipolar disorder, which comprises mixing the compound according to claim 14 with a pharmaceutically acceptable carrier.

28. (Previously presented) A method of treating psychotic conditions in a patient in need thereof, comprising administering to the patient an effective amount of a compound according to claim 14 .

29. (Previously presented) The pharmaceutical agent according to claim 3 wherein the psychotic condition is schizophrenia and/or bipolar disorder.

30. (Previously presented) The pharmaceutical agent according to claim 4 wherein the psychotic condition is schizophrenia and/or bipolar disorder.

31. (Previously presented) The pharmaceutical agent according to claim 5 wherein the psychotic condition is schizophrenia and/or bipolar disorder.

32. (Previously presented) The pharmaceutical agent according to claim 6 wherein the psychotic condition is schizophrenia and/or bipolar disorder.

33. (Previously presented) The pharmaceutical agent according to claim 7 wherein the psychotic condition is schizophrenia and/or bipolar disorder.

34. (Previously presented) The pharmaceutical agent according to claim 8 for use in therapy for schizophrenia and/or bipolar disorder.

35. (Previously presented) The pharmaceutical formulation according to claim 9 for use in therapy for schizophrenia and/or bipolar disorder.

36. (Previously presented) The method according to claim 11 wherein the psychotic condition is schizophrenia and/or bipolar disorder.

37. (Previously presented) The compound according to claim 19 wherein R^1 and R^2 form together with the nitrogen atom to which they are bonded, a four-membered, five-membered or six-membered cyclic amine.

38. (Previously presented) The compound according to claim 37 wherein said six-membered cyclic amine is fused with a benzene ring.

39. (Previously presented) The method according to claim 28 wherein the psychotic condition is schizophrenia and/or bipolar disorder.